ALGS · Aligos Therapeutics, Inc.

Aligos Therapeutics has licensed its investigational Hepatitis B compound pevifoscorvir sodium exclusively to Xiamen Amoytop Biotech for the Greater China region, covering mainland China, Taiwan, Hong Kong, and Macau. This deal provides immediate non-dilutive funding via a $25 million upfront payment and positions the Company for substantial future value through up to $420 million in milestones tied to development, regulatory, and commercial progress, plus ongoing high single-digit royalties on sales. The agreement becomes effective only upon Amoytop's shareholder approval, expected within 30 days and required within 45 days, introducing a near-term execution risk. Amoytop assumes full responsibility for all costs and efforts in development, regulatory filings, manufacturing, and commercialization, supported by joint committees and technical transfer from Aligos. This allows Aligos to retain global rights outside the Territory while offloading regional execution risk. Additional protections include Amoytop's commercially reasonable efforts obligation, milestone requirements, and a 7-year right of first negotiation for any new formulations with the same active ingredient. IP terms favor mutual benefit, with Amoytop owning its improvements but granting perpetual royalty-free licenses to Aligos for ex-Territory use, and quarterly data sharing. Termination rights for material breach, including milestone failures, safeguard Aligos' interests. Overall, this monetizes Aligos' asset in a key market without further investment, enhancing cash position and potential milestone inflows critical for a clinical-stage biotech.